Veronica C Beck1, Lori L Isom2, Anne T Berg3. 1. Neuroscience Graduate Program, University of Michigan, Ann Arbor, MI; Department of Pharmacology, University of Michigan, Ann Arbor, MI. 2. Neuroscience Graduate Program, University of Michigan, Ann Arbor, MI; Department of Pharmacology, University of Michigan, Ann Arbor, MI; Department of Neurology, University of Michigan, Ann Arbor, MI; Department of Molecular and Integrative Physiology, University of Michigan, Ann Arbor, MI. 3. Division of Neurology, Epilepsy Center, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL; Department of Pediatrics, Northwestern Feinberg School of Medicine, Chicago, IL. Electronic address: atberg@luriechildrens.org.
Abstract
OBJECTIVE: To determine the prevalence of and identify factors associated with gastrointestinal (GI) symptoms among children with channelopathy-associated developmental and epileptic encephalopathy (DEE). STUDY DESIGN: Parents of 168 children with DEEs linked to SCN1A (n = 59), KCNB1 (n = 31), or KCNQ2 (n = 78) completed online CLIRINX surveys about their children's GI symptoms. Our analysis examined the prevalence, frequency, and severity of GI symptoms, as well as DEE type, functional mobility, feeding difficulties, ketogenic diet, antiseizure medication, autism spectrum disorder (ASD), and seizures. Statistical analyses included the χ2 test, Wilcoxon rank-sum analysis, and multiple logistic regression. RESULTS: GI symptoms were reported in 92 of 168 patients (55%), among whom 63 of 86 (73%) reported daily or weekly symptoms, 29 of 92 (32%) had frequent or serious discomfort, and 13 of 91 (14%) had frequent or serious appetite disturbances as a result. The prevalence of GI symptoms varied across DEE cohorts with 44% of SCN1A-DEE patients, 35% of KCNB1-DEE patients, and 71% of KCNQ2-DEE patients reporting GI symptoms in the previous month. After adjustment for DEE type, current use of ketogenic diet (6% reported), and gastrostomy tube (13% reported) were both associated with GI symptoms in a statistically, but not clinically, significant manner (P < .05). Patient age, functional mobility, feeding difficulties, ASD, and seizures were not clearly associated with GI symptoms. Overall, no individual antiseizure medication was significantly associated with GI symptoms across all DEE cohorts. CONCLUSIONS: GI symptoms are common and frequently severe in patients with DEE.
OBJECTIVE: To determine the prevalence of and identify factors associated with gastrointestinal (GI) symptoms among children with channelopathy-associated developmental and epileptic encephalopathy (DEE). STUDY DESIGN: Parents of 168 children with DEEs linked to SCN1A (n = 59), KCNB1 (n = 31), or KCNQ2 (n = 78) completed online CLIRINX surveys about their children's GI symptoms. Our analysis examined the prevalence, frequency, and severity of GI symptoms, as well as DEE type, functional mobility, feeding difficulties, ketogenic diet, antiseizure medication, autism spectrum disorder (ASD), and seizures. Statistical analyses included the χ2 test, Wilcoxon rank-sum analysis, and multiple logistic regression. RESULTS: GI symptoms were reported in 92 of 168 patients (55%), among whom 63 of 86 (73%) reported daily or weekly symptoms, 29 of 92 (32%) had frequent or serious discomfort, and 13 of 91 (14%) had frequent or serious appetite disturbances as a result. The prevalence of GI symptoms varied across DEE cohorts with 44% of SCN1A-DEE patients, 35% of KCNB1-DEE patients, and 71% of KCNQ2-DEE patients reporting GI symptoms in the previous month. After adjustment for DEE type, current use of ketogenic diet (6% reported), and gastrostomy tube (13% reported) were both associated with GI symptoms in a statistically, but not clinically, significant manner (P < .05). Patient age, functional mobility, feeding difficulties, ASD, and seizures were not clearly associated with GI symptoms. Overall, no individual antiseizure medication was significantly associated with GI symptoms across all DEE cohorts. CONCLUSIONS: GI symptoms are common and frequently severe in patients with DEE.
Authors: Géza Berecki; Katherine B Howell; Yadeesha H Deerasooriya; Maria Roberta Cilio; Megan K Oliva; David Kaplan; Ingrid E Scheffer; Samuel F Berkovic; Steven Petrou Journal: Proc Natl Acad Sci U S A Date: 2018-05-29 Impact factor: 11.205
Authors: Peter R Strege; Adrian N Holm; Adam Rich; Steven M Miller; Yijun Ou; Michael G Sarr; Gianrico Farrugia Journal: Am J Physiol Cell Physiol Date: 2003-01 Impact factor: 4.249
Authors: G Richard Locke; Michael J Ackerman; Alan R Zinsmeister; Prabin Thapa; Gianrico Farrugia Journal: Am J Gastroenterol Date: 2006-06 Impact factor: 10.864
Authors: Peter R Strege; Yijun Ou; Lei Sha; Adam Rich; Simon J Gibbons; Joseph H Szurszewski; Michael G Sarr; Gianrico Farrugia Journal: Am J Physiol Gastrointest Liver Physiol Date: 2003-07-31 Impact factor: 4.052
Authors: Alec Aeby; Claudine Sculier; Alexandra A Bouza; Brandon Askar; Damien Lederer; Anne-Sofie Schoonjans; Marc Vander Ghinst; Berten Ceulemans; James Offord; Luis F Lopez-Santiago; Lori L Isom Journal: Ann Clin Transl Neurol Date: 2019-11-11 Impact factor: 4.511
Authors: Caroline R Fertleman; Mark D Baker; Keith A Parker; Sarah Moffatt; Frances V Elmslie; Bjarke Abrahamsen; Johan Ostman; Norbert Klugbauer; John N Wood; R Mark Gardiner; Michele Rees Journal: Neuron Date: 2006-12-07 Impact factor: 17.173